Skip to main content

Saxagliptin_Metformin

04-16-2019 | Nephropathy | News

Dapagliflozin–saxagliptin 'attractive' for type 2 diabetes with kidney disease

Dapagliflozin, with or without saxagliptin, reduces albuminuria in people with type 2 diabetes and moderate-to-severe chronic kidney disease when used in combination with antihypertensive treatments, DELIGHT study data show.

06-26-2018 | SGLT2 inhibitors | ADA 2018 | News

Dapagliflozin plus saxagliptin regimen shows promise for poorly controlled type 2 diabetes

Dapagliflozin plus saxagliptin offers a realistic alternative to both insulin and glimepiride in patients with type 2 diabetes poorly controlled by metformin, show two studies presented at the ADA’s 78th Scientific Sessions in Orlando, Florida, USA.

Testing blood pressure (symbolic image with models)

02-05-2018 | Cardiovascular outcomes | News

Low BP may flag cardiac risk in diabetes patients

Analysis of the SAVOR-TIMI trial supports a relationship between low blood pressure and cardiovascular risk in patients with type 2 diabetes.

06-12-2017 | Medications | ADA 2017 | News

Research round-up: medications for type 2 diabetes

One of the final sessions on Saturday featured the presentation of new, and mostly positive, data on medications for glycemic control in patients with type 2 diabetes.

09-28-2016 | Pancreatitis | News | Article

Pancreatitis risk small but real with gliptin treatment

A meta-analysis of randomised trials indicates that gliptin treatment is associated with a small but significantly increased risk of acute pancreatitis among patients with Type 2 diabetes.